Inflammatory carcinoma of the breast. Clinical review and summary of the vanderbilt experience with multi-modality therapy

Michael M. Sherry, David H. Johnson, David L. Page, F. Anthony Greco, John D. Hainsworth

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Inflammatory breast cancer is a distinct clinicopathologic entity that accounts for 1 percent of all cases of breast cancer. The diagnosis should be strongly suspected on the basis of the distinctive clinical findings, which include edema of the breast, inflammation, wheals, and a typical reddish-purple color of the overlying skin. Pathologic examination usually shows infiltration of the dermal lymphatics with carcinoma. Evidence of distant metastatic spread is more frequent than with other types of breast cancer and is seen in approximately 30 percent of patients. The five-year disease-free survival rate is less than 5 percent when local therapy alone (mastectomy and/or local radiotherapy) is used. The addition of combination chemotherapy to high-dose local radiotherapy has improved the five-year survival rate to approximately 30 percent. The potential for long-term survival is limited to the subgroup of patients with only local-regional disease at the time of diagnosis. Patients with inflammatory breast cancer should be treated with combined-modality therapy using combination chemotherapy and high-dose radiotherapy to the breast, since this approach is potentially curative. The fatalism formerly associated with this diagnosis is no longer warranted, particularly in patients with local-regional disease. Failure to employ Intensive combined-modality treatment will deny some patients a chance for long-term survival.

Original languageEnglish (US)
Pages (from-to)355-364
Number of pages10
JournalThe American journal of medicine
Volume79
Issue number3
DOIs
StatePublished - 1985

Fingerprint

Inflammatory Breast Neoplasms
Radiotherapy
Combination Drug Therapy
Breast
Survival Rate
Breast Neoplasms
Skin Pigmentation
Therapeutics
Combined Modality Therapy
Survival
Mastectomy
Disease-Free Survival
Edema
Inflammation
Carcinoma
Skin

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Inflammatory carcinoma of the breast. Clinical review and summary of the vanderbilt experience with multi-modality therapy. / Sherry, Michael M.; Johnson, David H.; Page, David L.; Greco, F. Anthony; Hainsworth, John D.

In: The American journal of medicine, Vol. 79, No. 3, 1985, p. 355-364.

Research output: Contribution to journalArticle

Sherry, Michael M. ; Johnson, David H. ; Page, David L. ; Greco, F. Anthony ; Hainsworth, John D. / Inflammatory carcinoma of the breast. Clinical review and summary of the vanderbilt experience with multi-modality therapy. In: The American journal of medicine. 1985 ; Vol. 79, No. 3. pp. 355-364.
@article{864896234e6b4d8d9860fa5ceeaf74e7,
title = "Inflammatory carcinoma of the breast. Clinical review and summary of the vanderbilt experience with multi-modality therapy",
abstract = "Inflammatory breast cancer is a distinct clinicopathologic entity that accounts for 1 percent of all cases of breast cancer. The diagnosis should be strongly suspected on the basis of the distinctive clinical findings, which include edema of the breast, inflammation, wheals, and a typical reddish-purple color of the overlying skin. Pathologic examination usually shows infiltration of the dermal lymphatics with carcinoma. Evidence of distant metastatic spread is more frequent than with other types of breast cancer and is seen in approximately 30 percent of patients. The five-year disease-free survival rate is less than 5 percent when local therapy alone (mastectomy and/or local radiotherapy) is used. The addition of combination chemotherapy to high-dose local radiotherapy has improved the five-year survival rate to approximately 30 percent. The potential for long-term survival is limited to the subgroup of patients with only local-regional disease at the time of diagnosis. Patients with inflammatory breast cancer should be treated with combined-modality therapy using combination chemotherapy and high-dose radiotherapy to the breast, since this approach is potentially curative. The fatalism formerly associated with this diagnosis is no longer warranted, particularly in patients with local-regional disease. Failure to employ Intensive combined-modality treatment will deny some patients a chance for long-term survival.",
author = "Sherry, {Michael M.} and Johnson, {David H.} and Page, {David L.} and Greco, {F. Anthony} and Hainsworth, {John D.}",
year = "1985",
doi = "10.1016/0002-9343(85)90314-6",
language = "English (US)",
volume = "79",
pages = "355--364",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Inflammatory carcinoma of the breast. Clinical review and summary of the vanderbilt experience with multi-modality therapy

AU - Sherry, Michael M.

AU - Johnson, David H.

AU - Page, David L.

AU - Greco, F. Anthony

AU - Hainsworth, John D.

PY - 1985

Y1 - 1985

N2 - Inflammatory breast cancer is a distinct clinicopathologic entity that accounts for 1 percent of all cases of breast cancer. The diagnosis should be strongly suspected on the basis of the distinctive clinical findings, which include edema of the breast, inflammation, wheals, and a typical reddish-purple color of the overlying skin. Pathologic examination usually shows infiltration of the dermal lymphatics with carcinoma. Evidence of distant metastatic spread is more frequent than with other types of breast cancer and is seen in approximately 30 percent of patients. The five-year disease-free survival rate is less than 5 percent when local therapy alone (mastectomy and/or local radiotherapy) is used. The addition of combination chemotherapy to high-dose local radiotherapy has improved the five-year survival rate to approximately 30 percent. The potential for long-term survival is limited to the subgroup of patients with only local-regional disease at the time of diagnosis. Patients with inflammatory breast cancer should be treated with combined-modality therapy using combination chemotherapy and high-dose radiotherapy to the breast, since this approach is potentially curative. The fatalism formerly associated with this diagnosis is no longer warranted, particularly in patients with local-regional disease. Failure to employ Intensive combined-modality treatment will deny some patients a chance for long-term survival.

AB - Inflammatory breast cancer is a distinct clinicopathologic entity that accounts for 1 percent of all cases of breast cancer. The diagnosis should be strongly suspected on the basis of the distinctive clinical findings, which include edema of the breast, inflammation, wheals, and a typical reddish-purple color of the overlying skin. Pathologic examination usually shows infiltration of the dermal lymphatics with carcinoma. Evidence of distant metastatic spread is more frequent than with other types of breast cancer and is seen in approximately 30 percent of patients. The five-year disease-free survival rate is less than 5 percent when local therapy alone (mastectomy and/or local radiotherapy) is used. The addition of combination chemotherapy to high-dose local radiotherapy has improved the five-year survival rate to approximately 30 percent. The potential for long-term survival is limited to the subgroup of patients with only local-regional disease at the time of diagnosis. Patients with inflammatory breast cancer should be treated with combined-modality therapy using combination chemotherapy and high-dose radiotherapy to the breast, since this approach is potentially curative. The fatalism formerly associated with this diagnosis is no longer warranted, particularly in patients with local-regional disease. Failure to employ Intensive combined-modality treatment will deny some patients a chance for long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=0021932309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021932309&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(85)90314-6

DO - 10.1016/0002-9343(85)90314-6

M3 - Article

C2 - 4036986

AN - SCOPUS:0021932309

VL - 79

SP - 355

EP - 364

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -